These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12763175)

  • 1. [Coagulation inhibitors in severe sepsis: state of the art].
    Fourrier F
    Rev Med Interne; 2003 May; 24(5):295-304. PubMed ID: 12763175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemostasis disorders in severe infections: state of the art].
    Fourrier F
    Med Mal Infect; 2006 Jun; 36(6):304-13. PubMed ID: 16713162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hemostasis disorders in severe infections: State of the art].
    Fourrier F
    Med Mal Infect; 2006 Oct; 36(10):524-533. PubMed ID: 17191328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor pathway inhibitor activity in severe sepsis.
    Creasey AA; Reinhart K
    Crit Care Med; 2001 Jul; 29(7 Suppl):S126-9. PubMed ID: 11445747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.
    Levi M; de Jonge E; van der Poll T
    Crit Care Med; 2001 Jul; 29(7 Suppl):S90-4. PubMed ID: 11445740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
    Papageorgiou C; Jourdi G; Adjambri E; Walborn A; Patel P; Fareed J; Elalamy I; Hoppensteadt D; Gerotziafas GT
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):8S-28S. PubMed ID: 30296833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
    Rice TW
    Vasc Health Risk Manag; 2006; 2(1):3-18. PubMed ID: 17319465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of heparin and allied compounds in the treatment of sepsis.
    Cornet AD; Smit EG; Beishuizen A; Groeneveld AB
    Thromb Haemost; 2007 Sep; 98(3):579-86. PubMed ID: 17849046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
    de Jonge E; van der Poll T; Kesecioglu J; Levi M
    Semin Thromb Hemost; 2001 Dec; 27(6):667-74. PubMed ID: 11740690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C versus protein C in severe sepsis.
    Yan SB; Dhainaut JF
    Crit Care Med; 2001 Jul; 29(7 Suppl):S69-74. PubMed ID: 11445737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of anticoagulant strategies on activation of inflammation and coagulation.
    Feistritzer C; Wiedermann CJ
    Expert Opin Biol Ther; 2007 Jun; 7(6):855-70. PubMed ID: 17555371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis.
    Bernard G; Artigas A; Dellinger P; Esmon C; Faist E; Faust SN; Fischer CJ; Fumagalli R; grinnell BW; Sprung C
    Crit Care Med; 2001 Jul; 29(7 Suppl):S75-7. PubMed ID: 11445738
    [No Abstract]   [Full Text] [Related]  

  • 14. Coagulation inhibitor substitution during sepsis.
    Fourrier F; Jourdain M; Tournois A; Caron C; Goudemand J; Chopin C
    Intensive Care Med; 1995 Nov; 21 Suppl 2():S264-8. PubMed ID: 8636534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation inhibitor replacement during sepsis: useless?
    Hoffman JN; Faist E
    Crit Care Med; 2000 Sep; 28(9 Suppl):S74-6. PubMed ID: 11007203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
    Al Otair HA; Abdel Gader AG; Khurshid SM; Alzeer AH; Al Momen AK; Al Shaikh M; Al Gahtani F; Al Aseri ZA; Abdelrazik HA
    Turk J Haematol; 2016 Jun; 33(2):112-8. PubMed ID: 26377606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic response to sepsis: interaction between coagulation and inflammatory processes.
    Dhainaut JF; Marin N; Mignon A; Vinsonneau C
    Crit Care Med; 2001 Jul; 29(7 Suppl):S42-7. PubMed ID: 11445733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protein C and coagulation in sepsis].
    D'Angelo A; Della Valle P; Giudici D; Viganò D'Angelo S
    Minerva Anestesiol; 2004 May; 70(5):339-50. PubMed ID: 15181414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.